drugset / Trial / NCT05029973
HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC
NaSingle-groupOpen-labelTreatment
Summary
To Evaluate the Efficacy and Safety of the Hepatic Arterial Infusion Chemotherapy(HAIC) Combined With Sintilimab and Bevacizumab Biosimilar in the Treatment of Patients With Unresectable Hepatocellular Carcinoma.
Timeline
- Start
- 2021-05-10
- Primary completion
- 2022-01-10
- Completion
- 2023-11-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Leucovorin | Small molecule | — | Other |
| Subject | Oxaliplatin | Small molecule | — | Other |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | fluorouracil | Small molecule | — | Other |